Finance

Lists
UNCY:NASDAQ
Unicycive Therapeutics Inc
4,19 USD
-0,71%
(-0,030) 1D
4,25 USD
+1,43% (+0,060)
After hours
Closed: 5-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UNCY...
Open
4,22 USD
High
4,28 USD
Low
4,12 USD
Mkt. cap
116,71 млн
Avg. vol.
860,62 миң
Volume
681,40 миң
52-wk high
8,74 USD
52-wk low
3,99 USD
EPS
-1,62 USD
Beta
1,83
Shares outstanding
27,86 млн
No. of employees
22
Open
4,22 USD
High
4,28 USD
Low
4,12 USD
Mkt. cap
116,71 млн
Avg. vol.
860,62 миң
Volume
681,40 миң
52-wk high
8,74 USD
52-wk low
3,99 USD
EPS
-1,62 USD
Beta
1,83
Shares outstanding
27,86 млн
No. of employees
22
News stories
From web sources and news partners
About Unicycive Therapeutics Inc
CEO-
Employees22
Founded2016
Headquarters-
Sector-
Websiteunicycive.com
Analyst ratings
Based on 6 analysts giving stock ratings to UNCY in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for UNCY in the last 3 months.
Highest
Current 4,19 USD
50,00 USD (+1 093,32%)
Average
25,50 USD (+508,59%)
Lowest
13,00 USD (+210,26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
13,00 USD
+210,3%
09/30/2026
Bruce Jackson
StoneX
Buy
Maintained
15,00 USD
+258%
08/20/2026
Jason McCarthy
Maxim Group
Buy
Maintained
30,00 USD
+616%
08/17/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
20,00 USD
+377,3%
08/13/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
50,00 USD
+1 093,3%
08/13/2026
Vamil Divan
Guggenheim
Buy
Maintained
25,00 USD
+496,7%
08/12/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
90,00 USD
+2 048%
06/01/2026
Unknown Analyst
Westpark Capital
Buy
Initiated
72,00 USD
+1 618,4%
02/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2,96 млн
2,25 млн
1,61 млн
2,79 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,38 млн
4,97 млн
6,83 млн
7,35 млн
Operating expense
7,34 млн
7,22 млн
8,44 млн
10,14 млн
Total operating expenses
7,34 млн
7,22 млн
8,44 млн
10,14 млн
Operating income
-7,34 млн
-7,22 млн
-8,44 млн
-10,14 млн
Other non operating income
1,07 млн
-7,77 млн
-4,78 млн
7,98 млн
EBT including unusual items
-6,01 млн
-14,67 млн
-12,82 млн
-1,72 млн
EBT excluding unusual items
-6,01 млн
-14,67 млн
-12,82 млн
-1,72 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6,01 млн
-14,67 млн
-12,82 млн
-1,72 млн
Net profit margin
-
-
-
-
Earnings per share
-0,33
-0,82
-0,54
-0,06
Interest and investment income
279,00 миң
351,00 миң
394,00 миң
441,00 миң
Interest expense
-15,00 миң
-27,00 миң
-
-
Net interest expenses
264,00 миң
324,00 миң
394,00 миң
441,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-7,33 млн
-7,21 млн
-8,43 млн
-10,13 млн
Gain or loss from assets sale
-
-
18,00 миң
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору